Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

S. Alice Long, Jerill Thorpe, Hannah A. DeBerg, +7

Science Immunology

Clinical ImmunologyT-regulatory CellImmunologyPathologyAntigen Processing +15

Comparison of commercial kits for detection of cryptococcal antigen

David C. Tanner, Melvin P. Weinstein, B Fedorciw, +3

Journal of Clinical Microbiology

Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, +19

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaTransplantationMarrow TransplantationLisocabtagene Maraleucel +8

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi, Jacob D. Soumerai, Kathleen Dorritie, +10

Blood

ImmunologyPrior TherapiesPathologyPharmacotherapyImmunotherapeutics +18

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes

S. Alice Long, Jerill Thorpe, Kevan C. Herold, +6

Cellular Immunology

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)

Lisa K. McNeil, Leah Price, Cedrik M. Britten, +8

Cytometry Part A

Immunocytochemical TechniqueImmunologyPathologyImmunophenotypingGate Uniformity +17

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, Kathleen Dorritie, Javier Muñoz, +8

Blood

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji Kumar, Shebli Atrash, +16

Blood

Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype

James D. Lord, S. Alice Long, Donna Shows, +5

Clinical Immunology

T-regulatory CellImmunologyImmune RegulationPathologyImmunologic Mechanism +16

Immunology of Diabetes Society T‐Cell Workshop: HLA class I tetramer‐directed epitope validation initiative T‐Cell Workshop Report—HLA Class I Tetramer Validation Initiative

Roberto Mallone, Matthieu Scotto, Claire N. Janicki, +11

Diabetes/Metabolism Research and Reviews